Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 70
- Registration Number
- NCT01614457
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 39
- Registration Number
- NCT01614470
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 359
- Registration Number
- NCT01590459
- Locations
- 🇺🇦
Vertex Investigational Site, Vinnytsia, Ukraine
VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 64
- Registration Number
- NCT01581138
A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 140
- Registration Number
- NCT01561807
Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 194
- Registration Number
- NCT01531673
- Locations
- 🇬🇧
Vertex Investigational Site, Cardiff, Vale Of Glamorgen, United Kingdom
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 103
- Registration Number
- NCT01516918
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2012-07-04
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 64
- Registration Number
- NCT01511432
- Locations
- 🇺🇸
Texas, Dallas, Texas, United States
🇺🇸Wisconsin, Madison, Wisconsin, United States
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 55
- Registration Number
- NCT01501383
- Locations
- 🇺🇸
Idaho, Boise, Idaho, United States
🇺🇸Virginia, Charlottesville, Virginia, United States
🇩🇪Germany, Kork, Germany
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 121
- Registration Number
- NCT01467492
- Locations
- 🇺🇸
Georgia, Atlanta, Georgia, United States
🇺🇸Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Washington, DC, Washington, District of Columbia, United States
© Copyright 2024. All Rights Reserved by MedPath